Get the Stockscreener App
15.50
3.61%
+0.54
Contineum Therapeutics Inc stock is currently priced at $15.50, with a 24-hour trading volume of 63,002.
It has seen a +3.61% increased in the last 24 hours and a +0.71% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $15.27 pivot point. If it approaches the $15.58 resistance level, significant changes may occur.
Previous Close:
$14.96
Open:
$14.75
24h Volume:
63,002
Market Cap:
$389.53M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-1.96%
1M Performance:
+0.71%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1D Range:
$14.75
$15.66
52W Range:
$13.27
$16.09
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Name
Contineum Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Contineum Therapeutics Inc Stock (CTNM) Latest News
Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - Business Wire
Business Wire
Morgan Stanley predicts a rally of up to 110% for these two 'Strong Buy' stocks - THE BHARAT - The Bharat Express News
The Bharat Express News
Morgan Stanley predicts a rally of up to 110% for these two 'Strong Buy' stocks - THE BHARAT - The Bharat Express News
The Bharat Express News
Contineum Therapeutics, Inc.'s Quiet Period Set To End on May 15th (NASDAQ:CTNM) - Defense World
Defense World
Despite dip in April, biopharma financings remain strong in 2024 - BioWorld Online
BioWorld Online
Contineum Therapeutics (NASDAQ:CTNM) Earns Outperform Rating from Analysts at Royal Bank of Canada - Defense World
Defense World
Contineum Therapeutics Inc Stock (CTNM) Financials Data
There is no financial data for Contineum Therapeutics Inc (CTNM). Check out other stocks for more information.
About Contineum Therapeutics Inc
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
0.77%
1.20%
Cap:
|
Volume (24h):